Cipla’s arm inks agreement with Avenue Therapeutics

13 Nov 2018 Evaluate

InvaGen Pharmaceuticals Inc., a subsidiary of the leading global pharmaceutical company Cipla, has entered into definitive agreements with two closing stages for a proposed acquisition of Avenue Therapeutics, Inc., a Fortress Biotech company focused on the development and commercialization of intravenous (IV) Tramadol.

At the first stage closing, InvaGen or its affiliates will acquire, through the issuance by Avenue of new shares, shares representing a 33.3% stake in Avenue’s capital stock on a fully diluted basis for $35 million.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1462.45 -3.70 (-0.25%)
12-Jan-2026 09:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.80
Dr. Reddys Lab 1202.30
Cipla 1462.45
Zydus Lifesciences 890.00
Lupin 2181.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×